I'IORRISON FOERSTER

2100 L STREET NW SUITE 900 WASHINGTON DC 20037

TELEPHONE: 202.887.1500 FACSIMILE: 202.887.0763

WWW.MOFO.COM

MORRISON & FOERSTER LLP

AMSTERDAM, AUSTIN, BERLIN, BOSTON, BRUSSELS, DENVER, HONG KONG, LONDON, LOS ANGELES, MIAMI, NEW YORK, PALO ALTO, SAN DIEGO, SAN FRANCISCO, SHANGHAI, SINGAPORE, TOKYO, WASHINGTON, D.C.

September 17, 2025

Writer's Direct Contact +1 (202) 887-8740 DMaynard@mofo.com

Honorable Scott S. Harris, Clerk Supreme Court of the United States 1 First Street NE Washington, DC 20543

Re: MSN Pharmaceuticals, Inc. et al. v. Novartis Pharmaceuticals Corporation, No. 25-225 Letter for an extension of time to file response

Dear Mr. Harris,

I am counsel of record for respondent Novartis Pharmaceuticals Corporation. After obtaining a 60-day extension, petitioners filed a petition for a writ of certiorari on August 22, 2025. After Novartis waived its right to respond, the Court requested a response, which is currently due October 8, 2025.

Under Rules 30.1 and 30.4, Novartis respectfully requests a 30-day extension of time, to and including November 7, 2025, in which to file its response to the petition. This is Novartis's first request for an extension on its response. As of today, Novartis has received notice that an additional amicus brief supporting the petition will be filed, and petitioners have indicated to the Court that there may be additional such briefs. Because those briefs need not be filed until October 8, 2025, an extension of time is necessary to afford Novartis the opportunity to review any assertions or argument made in them before filing its response. In addition, counsel for Novartis have multiple competing professional obligations in the coming weeks, including oral argument in the U.S. Court of Appeals for the Federal Circuit.

Respectfully submitted,

Dannellagea (

Deanne E. Maynard

cc: Amit R. Vora, Counsel of Record for Petitioners MSN Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; and MSN Life Sciences Private Ltd.

I'IORRISON FOERSTER

Honorable Scott S. Harris September 17, 2025 Page Two

RULE 29.6 CORPORATE DISCLOSURE STATEMENT

Counsel for respondent Novartis Pharmaceuticals Corporation state that Novartis Pharmaceuticals Corporation is a wholly owned indirect subsidiary of Novartis AG. No publicly traded company owns more than 10% of Novartis Pharmaceuticals Corporation's stock.

Dated: September 17, 2025

Deanne E. Maynard

I'IORRISON FOERSTER

Honorable Scott S. Harris September 17, 2025 Page Three

MSN PHARMACEUTICALS, INC. ET AL.

V.

NOVARTIS PHARMACEUTICALS CORPORATION

CERTIFICATE OF SERVICE

I, Deanne E. Maynard, certify that I am a member of the Bar of this Court, and that, in accordance with Rule 29.3, I have this 17th day of September, 2025, caused one copy of the above Letter For An Extension of Time to File Response to be served on the following counsel by third-party carrier and by electronic mail.

AMIT R. VORA KASOWITZ LLP 1633 Broadway New York, NY 10019 (212) 506-1834 avora@kasowitz.com

Counsel for Petitioners

Dated: September 17, 2025

Deanne E. Maynard